CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 103,800 shares, an increase of 91.5% from the February 29th total of 54,200 shares. Based on an average daily volume of 394,600 shares, the short-interest ratio is presently 0.3 days. Currently, 1.3% of the shares of the stock are sold short.

CNS Pharmaceuticals Trading Down 2.2 %

NASDAQ CNSP traded down $0.01 on Thursday, hitting $0.36. The company’s stock had a trading volume of 180,889 shares, compared to its average volume of 412,811. CNS Pharmaceuticals has a 1-year low of $0.23 and a 1-year high of $4.40. The company’s 50-day moving average is $0.36 and its 200 day moving average is $1.15.

Hedge Funds Weigh In On CNS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in CNS Pharmaceuticals by 145.6% in the 4th quarter. Vanguard Group Inc. now owns 58,369 shares of the company’s stock valued at $74,000 after acquiring an additional 34,604 shares during the period. Armistice Capital LLC acquired a new position in CNS Pharmaceuticals in the 4th quarter valued at approximately $155,000. Smith Anglin Financial LLC acquired a new stake in shares of CNS Pharmaceuticals during the fourth quarter worth $64,000. State Street Corp acquired a new stake in shares of CNS Pharmaceuticals during the second quarter worth $50,000. Finally, Geode Capital Management LLC acquired a new stake in shares of CNS Pharmaceuticals during the second quarter worth $36,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.